Abstract
CD59 overexpression has been shown to confer the resistance of tumors to complement lysis. Complement lysis is one of the two major killing mechanisms of therapeutic anticancer antibodies. This chapter provides a method that allows studying the extent of complement protection of tumors by CD59.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Gelderman K, Tomlinson S, Ross G et al (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25:158–164
Kolev M, Towner L, Donev R (2011) Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz) 59:407–419
Di Gaetano N, Cittera E, Nota R et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581–1587
Gelderman KA, Blok VT, Fleuren GJ et al (2002) The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 82:483–493
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Kolev, M. (2014). Functional Analysis of CD59 Using Complement-Dependent Cytotoxicity Assay. In: Gadjeva, M. (eds) The Complement System. Methods in Molecular Biology, vol 1100. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-724-2_29
Download citation
DOI: https://doi.org/10.1007/978-1-62703-724-2_29
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-723-5
Online ISBN: 978-1-62703-724-2
eBook Packages: Springer Protocols